As shown in Table 2, after a median follow-up of 4.25 years, 116 patients who used PDE5 inhibitors had died from CRC during the study period thus generating the mortality rate of 20.20 each 1000 person-year. The gene discussed is PDE5A; the disease is colorectal carcinoma.